普罗布考对早期糖尿病肾病患者血清超敏C反应蛋白和炎性因子表达的影响

普罗布考对早期糖尿病肾病患者血清超敏C反应蛋白和炎性
因子表达的影响
李荣霏;卢琼;易高众
【期刊名称】《中国药业》
【年(卷),期】2013(22)4
【摘要】Objective To observe the effect of probucol on the serum levels
of hs - CRP and inflammatory cytokines IL - 1 and IL - 6 in the patients with early - stage diabetic nephropathyC DN ). Methods 74 patients with early - stage DN were randomly divided into two groups,the routine treatment group and the probucol group. The probucol group was given probucol 500 mg,twice daily for 8 weeks,on the basis of the conventional treatment. The serum levels of glucose, lipid, UAER, hs - CRP, IL - 1 and IL - 6 before and after treatment were measured and compared between the two groups. Results There were no significant differences in the serum levels of TC,TG, HDL - C, LDL-CFBG, BUN, SCr, UAER, hs-CRP, IL-1 and IL - 6 between two groups before treatment(P > 0. 05 ). After 8 - week treatment, the serum levels of TC, TG, LDL - C, HDL - C, UAER, hs - CRP and IL-1 showed no obvious changes compared with those before treatment in the routine treatment group( P > 0.05), while the serum levels of TC, TG, LDL - C, UAER, hs - CRP, IL - 1 and IL - 6 in the probucol group were decreased significantly ( P < 0.05 or P < 0. 01 ). Compared with the routine treatment group, the serum levels of TC, TG, LDL - C, UAER, hs - CRP, IL - 1 and IL - 6
after 8-week treatment in the probucol group were decreased significantly ( P < 0. 05 or P < 0. 01 ). Conclusion Besides playing lipid - lowering effect, probucol can significantly decrease the serum levels of hs - CRP and inflammatory mediators IL-1 and IL - 6 in early - stage DN and delay the renal damage of DN.%目的观察普罗布考对早期糖尿病肾病患者血清超敏C反
应蛋白(hs-CRP)和炎性细胞因子白细胞介素1(IL-1)、白细胞介素6(IL-6)水平的影响.方法将74例患者随机分为常规治疗组(A组)和普罗布考组(B组).B组在常规治
疗基础上加用普罗布考500mg/次,每日2次,疗程8周.比较两组患者治疗前后血糖、血脂、24 h尿微量白蛋白排泄率(UAER)、hs-CRP及血清IL-1、IL-6水平.结果
治疗前两组血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、空腹血糖(FBG)、血尿素氮(BUN)、血肌酐(SCr)、UAER,hs-CRP,IL-1和IL-6水平比较,差异无统计学意义(P＞0.05).治疗第8周后,A组与治疗前比较,TC,TG,LDL-C,HDL-C,UAER,hs-CRP和IL-1水平无显著变化(P＞0.05);B
组与治疗前比较,TC,TG,LDL-C,UAER,hs-CRP,IL-1和IL-6水平显著下降(P＜0.05
或P＜0.01).与A组比较,B组治疗8周后TC,TG,LDL-C,UAER,hs-CRP,IL-1和IL-6水平显著下降(P＜0.05或P＜0.01).结论普罗布考在发挥降脂作用的同时,可显著
降低早期糖尿病肾病患者血清hs-CRP及炎症介质IL-1,IL-6的水平,延缓肾损害.【总页数】2页(P10-11)
【作者】李荣霏;卢琼;易高众
【作者单位】怀化医学高等专科学校,湖南,怀化,418000;怀化医学高等专科学校,湖南,怀化,418000;湖南省怀化市第一人民医院,湖南,怀化,418000
【正文语种】中文
【中图分类】R969.4;R972+.6
【相关文献】
1.普罗布考对早期糖尿病肾病患者血脂和炎性细胞因子hs-CRP、IL-1、IL-6水平的影响研究 [J], 赖名淦;梁海桥
2.缬沙坦对2型糖尿病早期糖尿病肾病患者血清超敏C反应蛋白水平的影响 [J], 黄宏超
3.普罗布考对早期糖尿病肾病患者炎症反应及纤维化程度的影响 [J], 李怀山;张颖丽;吴恩亮;王青青
4.普罗布考对早期糖尿病肾病患者氧化应激及转化生长因子-β1的影响 [J], 张玉静;刘倩
5.普罗布考对早期糖尿病肾病患者血清脂联素和BMP-7的影响 [J], 栾蓉;邱丽筠因版权原因，仅展示原文概要，查看原文内容请购买。